NCT02057523

Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: University of Illinois at Chicago · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.

Conditions

• Proteinuria
• Transplant Glomerulopathy

Interventions

Type	Name	Description
DRUG	Acthar	Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.

Timeline

• Start date: 2014-09-01
• Primary completion: 2015-03-01
• Completion: 2015-09-01
• First posted: 2014-02-07
• Last updated: 2020-09-04
• Results posted: 2020-09-04

Locations

1 site across 1 country: United States